AXCYNSIS THERAPEUTICS PTE. LTD.

Business Description

AXCYNSIS THERAPEUTICS PTE. LTD. is registered as a business entity on 21 February 2022 (2.6 years ago) structured as a Private Company Limited By Shares (Local Company) with 4 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 202205879C. The business official address is located at 41 Science Park Road #04-18, The Gemini, Singapore 117610 with main trading activity as Pharmaceutical Research And Development in the primary industry of 72106: Research And Experimental Development On Medical Science using Singapore Dollars - SGD as its default trading currency. The business legal name has undergone change(s) and is previously known as TETRIS THERAPEUTICS PTE. LTD.. The business annual account filing date falls on 31 July and is currently operational with the status of 'Live Company'. The business paid up share capital is USD 18,000, with preference share capital of USD 10,000,000, and other share capital at USD 0.

In the past 365 days, AXCYNSIS THERAPEUTICS PTE. LTD. has received a total of Login to view reported payment review(s). 8 were rated Good and Login to view were rated Poor. The latest review was made on 2023-08-17 and it was reported "Good". The aggregated good payment amount is equivalent to USD 5,888, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The lack of an appointed auditor indicates that the business is small sized as it did not meet the regulatory requirements of revenue or assets exceeding SGD 10 million, or has more than 50 employees in the previous two fiscal years.

AXCYNSIS THERAPEUTICS PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023